Fuchs endothelial corneal dystrophy

Determinants of Endothelial Cell Density One Year After DMEK: Insights from the Diabetes Endothelial Keratoplasty Study

By MedXY 08/04/2026

This analysis from the DEKS trial identifies donor endothelial damage, recipient diagnosis, and intraoperative complications as key factors influencing endothelial cell density at one year post-DMEK, highlighting the importance of donor tissue quality and operative care for graft survival.

news Ophthalmology

Ripasudil After DSO in Fuchs Endothelial Corneal Dystrophy: A Randomized Trial Signals a New Path to Corneal Recovery

By MedXY 06/19/2026

A phase 2 randomized trial found that topical ripasudil after DSO improved endothelial cell density, sped edema clearance, and reduced rescue therapy in FECD, especially with QID dosing.

news Ophthalmology

Genomic Risk Profiling May Help Predict Which Patients With Fuchs Endothelial Corneal Dystrophy Progress to Keratoplasty

By MedXY 05/27/2026

A 2026 Ophthalmology study suggests that combining CTG18.1 expansion testing with a FECD-specific polygenic risk score can improve prediction of keratoplasty risk across independent cohorts.